Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO1001 in advanced ErbB-positive cancer
ACTRN12620000583943Phase 2Recruiting
- Sponsor
- Senz Oncology
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of EO1001 in cancer (2 arms), sponsored by Senz Oncology. Primary endpoint: Safety and tolerability of EO1001. Started Sep 2021; status: recruiting.
02
Drugs
EO1001
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12620000583943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000583943.